Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2013 Feb 22;40(0 1):5–10. doi: 10.1007/s00259-013-2361-7

Fig. 3.

Fig. 3

Prognostic utility of FDG PET/CT in metastatic prostate cancer. Maximum intensity projection PET images show clinical states of castrate-sensitive predominantly lymph node disease at baseline (left panel) developing into castrate-resistant predominantly bone metastatic disease after 12 months (right panel). The patient died at 28.5 months after the baseline scan.